Skip to main content

Table 4 Plasma protein concentrations (fmol/μL) at baseline and at 6 weeks after SSRIs treatment

From: Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis

Protein Responder Nonresponder Responsiveness
Mean ± SD Uni-Pa Mean ± SD Uni-Pa Uni-Pb Multi-Pc
At baseline At 6 week At baseline At 6 week
N 19   16    
AGP1 8325 ± 2672 7916 ± 2084 0.455 8014 ± 3334 7888 ± 2856 0.433 0.540 0.954
HGFA 5.44 ± 3.60 4.50 ± 1.64 0.374 4.00 ± 1.55 4.01 ± 1.53 0.968 0.141 0.193
LBP 28.8 ± 13.2 32.0 ± 9.58 0.290 33.6 ± 17.6 30.0 ± 9.54 0.706 0.362 0.053
Prothrombin 1485 ± 294 1499 ± 172 0.728 1450 ± 316 1405 ± 325 0.744 0.733 0.294
SeP 137 ± 37.1 148 ± 16.5 0.237 129 ± 36.9 122 ± 38.2 0.464 0.417 0.465
TBG 118 ± 27.9 129 ± 24.9 0.090 128 ± 36.9 124 ± 24.9 0.336 0.354 0.370
Transthyretin 6105 ± 1689 6448 ± 1444 0.361 6016 ± 1681 5864 ± 1867 0.585 0.876 0.351
  1. HAM-D Hamilton Depression Rating Scale, SD standard deviation, SSRIs selective serotonin reuptake inhibitors
  2. aP-value from Wilcoxon signed rank test or paired T-test between at baseline and at 6 weeks in each response group
  3. bP-value from Mann–Whitney test or T-test between responders and nonresponders at baseline
  4. cMultivariable P-value from partial Spearman correlation analysis including clinical variables with P < 0.020 (HAM-D score at baseline, number of episode, and duration of current episode)